Kristin Sherman

Kristin Sherman is the CEO of Kovina Therapeutics, an early-stage biotech company focused on developing antiviral therapeutics specifically designed to treat premalignant infections and cancers caused by human papillomavirus.

Prior to Kovina, Kristin served as the COO of VMS BioMarketing, a healthcare marketing firm focused on improving patient outcomes. Her prior experience includes serving as chief financial officer for private biotech companies such as Calibrium LLC until its acquisition by Novo Nordisk in 2015, and Marcadia Biotech, which was purchased by Roche in 2010. Kristin also worked as the vice president and treasurer for Guidant Corp. and served as the company’s first financial director for the emerging markets region located in Belgium. In addition, she served as Guidant’s assistant treasurer during the company’s spinoff from Eli Lilly and Co. Kristin began her career in finance with Eli Lilly and Co.

Kristin was named by the Indianapolis Business Journal as a Woman of Influence. Kristin earned her bachelor of arts in economics from DePauw University, achieving summa cum laude distinction and graduating Phi Beta Kappa. She earned an MBA from the Tuck School of Business at Dartmouth, achieving Tuck Scholar distinction. She was also a board member and chair of the Audit Committee for Lacy Diversified Industries and previously served on various community boards.

Kristin is the chair of the Community Health Network board of directors and is the past chair of the Audit, Compliance and Finance Committee.